Jay Endres, MD
Family Medicine · Warren, PANPI 1073581948
Payments from drug & device makers
Across 260 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$591
- Novo Nordisk$559
- Pfizer$465
- Lilly USA, LLC$245
- Otsuka America Pharmaceutical, Inc.$223
- Boston Scientific$206
- plus $2K from 28 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$3,80098%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $591 |
| Novo Nordisk | 49 | $559 |
| Pfizer | 33 | $465 |
| Lilly USA, LLC | 16 | $245 |
| Otsuka America Pharmaceutical, Inc. | 13 | $223 |
| Boston Scientific | 4 | $206 |
| GSK | 12 | $178 |
| Johnson & Johnson | 12 | $155 |
| Exact Sciences | 9 | $146 |
| Amarin Pharma, Inc. | 8 | $141 |
| Amgen | 7 | $105 |
| Novartis | 8 | $102 |
| E.r. Squibb & Sons, L.L.C. | 6 | $87 |
| Astellas Pharma US Inc | 6 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $77 |
| Grifols USA, LLC | 4 | $71 |
| AbbVie(2 entities) | 3 | $41 |
| Biohaven Pharmaceuticals, Inc. | 3 | $40 |
| Collegium Pharmaceutical, Inc. | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Abbott | 2 | $31 |
| Urovant Sciences Inc | 2 | $31 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Dexcom, Inc. | 2 | $29 |
| Boehringer Ingelheim | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Biogen | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$144
- BREZTRI$125
How this compares
$3,875 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 877 | $363,895 |
| XareltoRivaroxaban | 326 | $193,146 |
| TrulicityDulaglutide | 166 | $156,794 |
| RexultiBrexpiprazole | 175 | $127,679 |
| OzempicSemaglutide | 106 | $114,159 |
| EntrestoSacubitril/Valsartan | 145 | $67,070 |
| MyrbetriqMirabegron | 255 | $60,894 |
| MounjaroTirzepatide | 49 | $52,189 |
| XifaxanRifaximin | 27 | $39,440 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $36,707 |
| FarxigaDapagliflozin Propanediol | 70 | $29,652 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $29,308 |
| RybelsusSemaglutide | 19 | $26,135 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 69 | $25,368 |
| Potassium Chloride | 1,354 | $23,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $465 | $363,895877 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $245 | $208,984215 claims |
| Johnson & JohnsonXarelto | $155 | $193,146326 claims |
| Novo NordiskOzempic, Rybelsus | $559 | $140,294125 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $223 | $127,679175 claims |
| NovartisEntresto | $102 | $67,070145 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $60,894255 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $591 | $58,960107 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $178 | $49,16973 claims |
| Boehringer IngelheimTradjenta, Jardiance | $25 | $22,82551 claims |
| AbbVieLumigan | $41 | $9,08334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Warren
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.